Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.67 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3867553 | 0.88 | MAPT (0.56) | MAPTL3MBTL1HPGDALDH1A1CYP2C9 | |
| SCHEMBL9463 | 0.86 | ACHE (0.70) | MAPTL3MBTL1HPGDALDH1A1CYP2C9 | |
| Ammonia Solution, Strong SCHEMBL28912190 | 0.84 | ACHE (0.67) | MAPTL3MBTL1HPGDALDH1A1CYP2C9 | |
| SCHEMBL22198921 | 0.81 | ACHE (0.52) | MAPTL3MBTL1HPGDALDH1A1CYP2C9 | |
| SCHEMBL19853644 | 0.80 | AR (0.58) | MAPTL3MBTL1HPGDALDH1A1CYP2C9 | |
| SCHEMBL7921257 | 0.79 | MAPT (0.50) | MAPTL3MBTL1HPGDALDH1A1CYP2C9 | |
| SCHEMBL7921254 | 0.79 | MAPT (0.50) | MAPTL3MBTL1HPGDALDH1A1CYP2C9 | |
| SCHEMBL14516844 | 0.79 | MAPT (0.50) | MAPTL3MBTL1HPGDALDH1A1CYP2C9 | |
| Chloroneb SCHEMBL22739 | 0.79 | GAA (0.64) | MAPTHPGDALDH1A1MAPK1MEN1 | |
| SCHEMBL27985066 | 0.79 | MAPT (0.54) | MAPTL3MBTL1HPGDALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 783 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522619-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-RE50453-E1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| CN-119823097-A | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119569553-A | Preparation method and application of 3-methoxy-4-chlorobenzaldehyde | 苏州亚科科技股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-115551845-B | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4463462-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118715231-A | Complement factor inhibitors and uses thereof | 安尼艾克松股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2024-03-21 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| EP-0686625-B1 | ANTHRANILIC ACID DERIVATIVE | EISAI CO LTD (JP) | 1999-05-26 | — | — | EP | disclosed |
| US-5716993-A | PHOSPHODIESTERASE ENZYME INHIBITOR FOR TREATING CARDIOVASCULAR DISORDER, ANGINA PECTORIS, HYPERTENSION, ASTHMA | EISAI CO., LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| US-5631264-A | NEUROLOGICAL DISORDERS | SANOFI WINTHROP, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0772601-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5554620-A | Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof | STERLING WINTHROP INC. (US) | 1996-09-10 | — | — | US | disclosed |
| WO-1996003387-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| EP-0686625-A1 | ANTHRANILIC ACID DERIVATIVE | Eisai Co., Ltd. (JP) | 1995-12-13 | — | — | EP | disclosed |
| EP-0656359-A1 | Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts and compositionsand methods of use thereof | STERLING WINTHROP INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| US-4727180-A | SIDE EFFECT REDUCTION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MAPT 4484/4885L3MBTL1 3601/4885HPGD 1644/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | MAPT 3674/4885L3MBTL1 3936/4885HPGD 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.